Previous 10 | Next 10 |
home / stock / imv:cc / imv:cc news
Early analysis reveals clinically meaningful activity in refractory DLBCL patients Multiple confirmed complete responses observed in heavily pre-treated patients No adverse safety and tolerability signal reported, consistent with previous clinical trials IMV Inc. (Nasdaq...
Presenting details on initial response data from the ongoing VITALIZE DLBCL trial at the Immuno-Oncology 360° conference on February 10, 2023 Expects preliminary clinical response data from the AVALON Phase 2b trial in H2 2023 Recently strengthened financial position with the...
IMV Inc. (“IMV” or the “Company”) (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company advancing a portfolio of therapies based on the Company’s immune-educating platform, DPX ® , to potentially treat solid and hematologic cancers, announ...
IMV Inc. (“IMV” or the “Company”) (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company advancing a portfolio of therapies based on the Company’s immune-educating platform, DPX ® , to potentially treat solid and hematologic cancers, announ...
Complete responses were observed in patients who received at least three previous lines of treatment (including CAR-T's) Recent clinical data add to the growing enthusiasm for the therapeutic potential of cancer vaccines in combination with checkpoint inhibitors Oral presentation ...
IMV Inc. (the “Corporation” or “IMV”) (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, announced that its common shares...
IMV’s common shares expected to begin trading on a split-adjusted basis on December 13, 2022 IMV Inc. (the “Corporation”) (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX&...
IMV Inc. (“ IMV ” or the “ Company ”) (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX ® platform to treat solid and hematologic cancers, today announced that, on No...
IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or the “Company”), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX ® platform to treat solid and hematologic cancers, today announced its f...
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX ® platform to treat solid and hematologic cancers, today announced that it will hold a conference call and webcast on Friday, November 11, 2022...
News, Short Squeeze, Breakout and More Instantly...
Imv Inc. Company Name:
IMV:CC Stock Symbol:
TSXC Market:
IMV Inc. (the “ Company ” or “ IMV ”) announces today that it has accepted an offer (the “ Offer ”) from IMV’s largest secured creditors (the “ Secured Lenders ”), pursuant to which IMV and its subsidiary, Immunovaccin...
IMV Inc. (the “ Company ” or “ IMV ”), recently announced an update on the Sales and Investment Solicitation Process (the “ SISP ”) implemented as part of its ongoing proceedings under the Companies' Creditors Arrangement Act (the “...
IMV Inc. (the “ Company ” or “ IMV ”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX ® platform to treat solid and hematologic cancers, today announced tha...